Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Real-World study shows dupilumab may ease severe asthma symptoms

NCT ID NCT06018441

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 22 times

Summary

This study followed 112 adults with severe asthma who started taking dupilumab (Dupixent®) to see how their quality of life changed over a year. Researchers measured breathing, activity, and emotional well-being using a standard questionnaire. The goal was to understand the drug's real-world benefits beyond controlled clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Investigational Site

    France, France

Conditions

Explore the condition pages connected to this study.